Analysts See $-0.52 EPS for Cellular Biomedicine Group, Inc. (CBMG)

July 14, 2018 - By Ash Ash

Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) LogoInvestors sentiment increased to 2.6 in Q1 2018. Its up 1.89, from 0.71 in 2017Q4. It improved, as 2 investors sold Cellular Biomedicine Group, Inc. shares while 3 reduced holdings. 8 funds opened positions while 5 raised stakes. 685,017 shares or 44.95% more from 472,598 shares in 2017Q4 were reported.
The North Carolina-based Bankshares Of America Corporation De has invested 0% in Cellular Biomedicine Group, Inc. (NASDAQ:CBMG). 21,197 were reported by Dimensional Fund Advisors Limited Partnership. Goldman Sachs Grp reported 0% of its portfolio in Cellular Biomedicine Group, Inc. (NASDAQ:CBMG). 58,085 were reported by Geode Capital Mngmt Ltd Llc. Bridgeway Cap Management Inc has invested 0.01% of its portfolio in Cellular Biomedicine Group, Inc. (NASDAQ:CBMG). Bnp Paribas Arbitrage Sa accumulated 7 shares. The California-based West Oak Capital Limited Liability Company has invested 0% in Cellular Biomedicine Group, Inc. (NASDAQ:CBMG). Susquehanna Intl Llp accumulated 43,028 shares or 0% of the stock. Morgan Stanley reported 0% stake. Blackrock Inc stated it has 0% of its portfolio in Cellular Biomedicine Group, Inc. (NASDAQ:CBMG). Sei holds 0% of its portfolio in Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) for 3,814 shares. 193 are held by Stratos Wealth Ptnrs. Moreover, Vanguard Gp has 0% invested in Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) for 142,033 shares. Moreover, State Street has 0% invested in Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) for 11,329 shares. Bancshares Of Mellon Corporation stated it has 0% of its portfolio in Cellular Biomedicine Group, Inc. (NASDAQ:CBMG).

Since April 10, 2018, it had 0 insider purchases, and 1 insider sale for $450,832 activity.

Analysts expect Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) to report $-0.52 EPS on August, 14.They anticipate $0.09 EPS change or 20.93 % from last quarter’s $-0.43 EPS. After having $-0.51 EPS previously, Cellular Biomedicine Group, Inc.’s analysts see 1.96 % EPS growth. The stock decreased 2.26% or $0.45 during the last trading session, reaching $19.45. About 92,349 shares traded or 54.13% up from the average. Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) has risen 210.91% since July 14, 2017 and is uptrending. It has outperformed by 198.34% the S&P500.

Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) Ratings Coverage

Among 2 analysts covering Cellular Biomedicine Group (NASDAQ:CBMG), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Cellular Biomedicine Group had 3 analyst reports since February 1, 2018 according to SRatingsIntel. The stock of Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) has “Hold” rating given on Thursday, February 1 by Maxim Group. On Thursday, March 8 the stock rating was initiated by FBR Capital with “Buy”.

Cellular Biomedicine Group Inc., a biopharmaceutical company, develops treatments for cancerous and degenerative diseases in Greater China. The company has market cap of $330.77 million. It focuses on developing and marketing cell therapies to treat serious diseases, such as cancer, orthopedic, and various inflammatory diseases, as well as metabolic diseases. It currently has negative earnings. The firm develops treatments utilizing proprietary cell based technologies, including immune cell therapy for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint and autoimmune diseases; and tumor cell specific dendritic cell therapy.

More news for Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) were recently published by: Prnewswire.com, which released: “Rise of Chronic Diseases Leads to Growing Investment in Stem Cell Research” on July 11, 2018. Globenewswire.com‘s article titled: “Cellular Biomedicine Group to Present a Keynote Address at CAR-TCR Summit Asia” and published on June 21, 2018 is yet another important article.

Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: